What the FDA labels say about taking them together
Carboplatin and paclitaxel
Paclitaxel's FDA label (Paclitaxel) of November 1, 2023 names carboplatin in its warnings and precautions section; the carboplatin labels PlainMeds reads (2) do not name paclitaxel. The paclitaxel label: “In patients with NSCLC, resume treatment if recommended at permanently reduced doses for both weekly ABRAXANE and every-3-week carboplatin after ANC recovers to at least 1500 cells/mm 3 and platelet count of at least …”
Check it at the source: the carboplatin FDA label on DailyMed (effective January 10, 2025, Eugia US LLC); the paclitaxel FDA label on DailyMed (effective January 21, 2026, Natco Pharma USA LLC).
What does the carboplatin label say about paclitaxel?
Carboplatin's label (effective January 10, 2025) and its 1 other brand-application label do not name paclitaxel in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (CARBOPLATIN), Eugia US LLC, effective January 10, 2025 (SPL set f5fe9a20-47a5-45b9-ab06-c6158d9b6aca), via openFDA; the full label on DailyMed
What does the paclitaxel label say about carboplatin?
Paclitaxel label (Teva Pharmaceuticals, Inc., November 1, 2023), warnings and precautionsIn patients with NSCLC, resume treatment if recommended at permanently reduced doses for both weekly protein-bound paclitaxel for Injectable Suspension (albumin-bound) and every-3-week carboplatin after ANC recovers to at least 1,500 cells/mm 3 and platelet count of at least 100,000 cells/mm 3 on Day 1 or to an ANC of at least 500 cells/mm 3 and platelet count of at least 50,000 cells/mm 3 on Days 8 or 15 of the cycle [see Dosage and Administration ( 2.6 )].
Source: FDA drug label (Paclitaxel, NDA216338), Teva Pharmaceuticals, Inc., effective November 1, 2023 (SPL set 15dd51ed-29e8-468b-b6d1-21b1f84d6f2e), via openFDA
Source: FDA drug label (Paclitaxel Protein Bound Particles Albumin Bound, NDA211875), American Regent, Inc., effective May 1, 2023 (SPL set f06d1bb3-83f1-4d84-8004-4c6681ad8a5a), via openFDA
Source: FDA drug label (Abraxane, NDA021660), Abraxis BioScience, LLC, effective October 31, 2022 (SPL set 24d10449-2936-4cd3-b7db-a7683db721e4), via openFDA
Source: FDA drug label (Paclitaxel), Natco Pharma USA LLC, effective January 21, 2026 (SPL set a1eb16b4-285b-4e81-9c4e-1244d4a52af8), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Carboplatin | Paclitaxel | |
|---|---|---|
| Labeled for | n/a | Breast cancer, Lung cancer |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | In shortage | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once